Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Objective: The clinical benefit of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) has never been reported in absolute measures. The aim of this study was to assess the number needed to treat (NNT) with UDCA to prevent liver transplantation (LT) or death among patients with PBC. Methods: The NNT was calculated based on the untreated LT-free survival and HR of UDCA with respect to LT or death as derived from inverse probability of treatment weighting-adjusted Cox proportional hazard analyses within the Global PBC Study Group database. Results: We included 3902 patients with a median follow-up of 7.8 (4.1–12.1) years. The overall HR of UDCA was 0.46 (95% CI 0.40 to 0.52) and the 5-year LT-free survival without UDCA was 81% (95% CI 79 to 82). The NNT to prevent one LT or death within 5 years (NNT 5y) was 11 (95% CI 9 to 13). Although the HR of UDCA was similar for patients with and without cirrhosis (0.33 vs 0.31), the NNT 5y was 4 (95% CI 3 to 5) and 20 (95% CI 14 to 34), respectively. Among patients with low alkaline phosphatase (ALP) (≤2× the upper limit of normal (ULN)), intermediate ALP (2–4× ULN) and high ALP (>4× ULN), the NNT 5y to prevent one LT or death was 26 (95% CI 15 to 70), 11 (95% CI 8 to 17) and 5 (95% CI 4 to 8), respectively. Conclusion: The absolute clinical efficacy of UDCA with respect to LT or death varied with baseline prognostic characteristics, but was high throughout. These findings strongly emphasise the incentive to promptly initiate UDCA treatment in all patients with PBC and may improve patient compliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationKaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Self-citationPrognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Self-citationChazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Self-citation
Research works printed but not linked: 14
- Carey, 2015, Primary biliary cirrhosis, The Lancet, 386, 1565, 10.1016/S0140-6736(15)00154-3 · DOI · Paper page
- Prince, 2002, Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years, Gastroenterology, 123, 1044, 10.1053/gast.2002.36027 · DOI · Paper page
- 2014, Working subgroup for clinical practice guidelines for primary biliary C. guidelines for the management of primary biliary cirrhosis: the intractable hepatobiliary disease Study Group supported by the Ministry of health, labour and welfare of Japan, Hepatol Res, 44, 71, 10.1111/hepr.12270 · DOI
- Haboubi, 2019, FRI-057-A review of primary biliary cholangitis practice in Wales: time for specialist care, J Hepatol, 70, e409, 10.1016/S0618-8278(19)30807-2 · doi:10.1016/s0618-8278(19)30807-2
- Lu, 2018, Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment, Clin Gastroenterol Hepatol, 16, 1342, 10.1016/j.cgh.2017.12.033 · DOI · Paper page
- Robins, 2000, Marginal structural models and causal inference in epidemiology, Epidemiology, 11, 550, 10.1097/00001648-200009000-00011 · DOI · Paper page
- Austin, 2014, The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments, Stat Med, 33, 1242, 10.1002/sim.5984 · DOI · Paper page
- Heagerty, 2005, Survival model predictive accuracy and ROC curves, Biometrics, 61, 92, 10.1111/j.0006-341X.2005.030814.x · DOI · Paper page
- Naylor, 1992, Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?, Ann Intern Med, 117, 916, 10.7326/0003-4819-117-11-916 · DOI · Paper page
- Caverly, 2014, Confusing relative risk with absolute risk is associated with more Enthusiastic beliefs about the value of cancer screening, Med Decis Making, 34, 686, 10.1177/0272989X14526641 · DOI
- Bucher, 1994, Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration, BMJ, 309, 761, 10.1136/bmj.309.6957.761 · DOI · Paper page
- Saffioti F , Gurusamy KS , Eusebi LH , et al . Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;28.doi:10.1002/14651858.CD011648 · DOI · Paper page
- Lefkowitch, 2007, Liver biopsy assessment in chronic hepatitis, Arch Med Res, 38, 634, 10.1016/j.arcmed.2006.08.005 · DOI
- ter Borg, 2006, Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients, Am J Gastroenterol, 101, 2044, 10.1111/j.1572-0241.2006.00699.x · DOI · Paper page
Cited by
Corpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000529 · Cited by 94
Self-citationPrimary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000864 · Cited by 38
Self-citationTreatment of Primary Biliary Cholangitis
Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.012 · Cited by 9
Advancing care in primary biliary cholangitis: emerging insights and novel therapies
Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516622 · Cited by 5
Dunn, S., Evans, L., Kennedy, C., Wafer, R., Moody, S., Wolstenhulme, F., Burton, E., Konkoth, A. B., Fisher, H., Chadwick, T., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-113812
Self-citation
Metadata
- Authors
- Harms, M. H., de Veer, R. C., Lammers, W. J., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Trivedi, P. J., Hirschfield, G. M., Pares, A., Floreani, A., Mayo, M. J., Invernizzi, P., Battezzati, P. M., Nevens, F., Ponsioen, C. Y., Mason, A. L., Kowdley, K. V., Hansen, B. E., Buuren, H. R. V., & van der Meer, A. J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2019-12-16
- Volume
- 69
- Issue
- 8
- Pages
- 1502-1509
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2995022330
- Cited by
- 46
- References
- 13
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Intercept pharmaceuticals (Unrestricted grant)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. https://app.cochat.ai/papers/10.1136/gutjnl-2019-319057
- The paper
- Harms, M. H., de Veer, R. C., Lammers, W. J., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Trivedi, P. J., Hirschfield, G. M., Pares, A., Floreani, A., Mayo, M. J., Invernizzi, P., Battezzati, P. M., Nevens, F., Ponsioen, C. Y., Mason, A. L., Kowdley, K. V., Hansen, B. E., . . . van der Meer, A. J. (2020). Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut. https://doi.org/10.1136/gutjnl-2019-319057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.